Chris Horvath

Chris Horvath is an accomplished executive in the pharmaceutical and biotechnology sectors, currently serving as Chief Commercial Officer & Chief Operating Officer at AdvanCell since May 2024, specializing in Targeted Alpha Therapies in Oncology. Prior to this role, Chris held significant positions including Executive Vice President of Commercial at POINT Biopharma, where the focus was on next-generation radioligand therapies, and Vice President and Head of the Prostate Cancer Franchise at Advanced Accelerator Applications, leading the US commercial launch of notable products. Chris's extensive career includes leadership roles at Bayer Pharmaceuticals, Merck, Dendreon, and Janssen Inc., primarily centered around oncology and urology marketing. Educational qualifications include an MBA in Pharmaceutical Management & Marketing from Rutgers Business School, alongside a MSc in Analytical Science and a BSc in Chemistry & Biology from Canadian institutions.